Highlights
- The vast majority (71.7%) of older adults with advanced cancer prioritize maintaining quality of life (QoL) over extending survival (8.4%).
- Clinical outcomes, including Grade 3-5 treatment-related adverse effects (TRAEs) and hospitalizations, did not differ significantly between patients prioritizing survival versus those prioritizing QoL.
- Median survival at 6 months and 1 year showed no statistically significant difference based on patient preference, highlighting a potential misalignment between patient goals and actual oncology care delivery.
- The findings suggest that the current oncology infrastructure may offer a ‘one-size-fits-all’ treatment intensity that fails to adjust based on individualized patient values.
Background
In the evolving landscape of geriatric oncology, the ‘silver tsunami’ has brought to the forefront a critical challenge: how to provide evidence-based cancer care that aligns with the unique values and physiological vulnerabilities of older adults. For patients with advanced, incurable malignancies, the primary goals of care often fluctuate between extending the duration of life and maximizing the quality of the remaining time. While health policy and clinical guidelines increasingly emphasize ‘patient-centered care,’ there is a paucity of empirical data demonstrating whether articulating these preferences actually leads to divergent clinical outcomes.
Older adults (aged ≥70 years) often present with multiple comorbidities, functional impairments, and geriatric syndromes that complicate systemic therapy. The Geriatric Assessment (GA) has emerged as a gold standard tool to identify these vulnerabilities. However, even when GA is utilized, the question remains: does the oncology care system possess the agility to de-escalate or intensify treatment in a way that respects a patient’s stated priority for either QoL or survival? This analysis, derived from the landmark GAP70+ cluster randomized clinical trial, seeks to answer this by examining the correlation between patient preferences and downstream clinical results.
Key Content
Study Design and Methodological Framework
The GAP70+ trial (NCT02054741) was a nationwide, cluster randomized clinical trial conducted across the National Cancer Institute (NCI) Community Oncology Research Program (NCORP) centers. The primary trial demonstrated that providing geriatric assessment results with management recommendations to oncologists significantly reduced the incidence of Grade 3-5 toxicities in older adults starting new systemic treatments.
This exploratory secondary analysis focused on 706 participants aged 70 and older with incurable solid tumors or lymphoma. Each participant had at least one impaired GA domain. Patients were categorized into two cohorts based on their response to a validated preference query: those prioritizing survival and those prioritizing QoL. The analysis specifically tracked treatment modifications, Grade 3-5 TRAEs, hospitalizations, and survival at 6 and 12 months.
Patient Demographics and Preference Distribution
The study population (mean age 77.2 years; 56.7% male) represented a broad spectrum of advanced cancers, including gastrointestinal (34.6%), lung (24.8%), and genitourinary (15.4%). A striking finding was the distribution of preferences: only 8.4% (n=59) of patients prioritized extending survival. In contrast, 71.7% (n=506) prioritized maintaining QoL. This stark contrast highlights a significant skew in the elderly population toward value-based outcomes rather than purely quantitative longevity.
Clinical Outcomes: The Responsiveness Gap
The central hypothesis of the study—that patients prioritizing survival would live longer while those prioritizing QoL would experience fewer toxicities—was not supported by the data. The following results were observed:
- Treatment Modifications: There was no significant difference in up-front treatment modifications between the two groups (Risk Ratio 1.03; 95% CI, 0.84-1.27).
- Adverse Events: The risk of Grade 3 to 5 TRAEs was not significantly lower for the QoL group (Hazard Ratio [HR], 0.84; 95% CI, 0.57-1.23).
- Hospitalization: Hospitalization rates remained comparable (HR, 0.74; 95% CI, 0.39-1.41).
- Survival: Survival at 1 year showed no significant difference (HR, 1.18; 95% CI, 0.81-1.72), suggesting that prioritizing survival did not actually confer a survival benefit in this population.
Expert Commentary
The results of this GAP70+ secondary analysis reveal a profound ‘responsiveness gap’ in modern oncology. Despite the clear articulation of preferences by older adults, the clinical trajectory—from the intensity of initial treatment to the incidence of severe toxicity—remained largely uniform across preference groups. This suggests that the oncology care delivery system may be operating on a default setting of ‘maximum tolerated intensity’ regardless of whether the patient values QoL above all else.
From a mechanistic perspective, this lack of divergence may be attributed to several factors. First, oncologists may lack the specific training or communication tools required to translate a ‘QoL preference’ into a concrete, modified treatment plan (e.g., dose reductions or selecting agents with better side-effect profiles). Second, institutional pressures and standardized pathways often incentivize aggressive treatment protocols even in palliative settings. Third, there is a pervasive clinical fear that ‘doing less’ will lead to rapid disease progression, even when the patient has explicitly accepted that risk in favor of better daily functioning.
Controversially, the data also show that those who *did* prioritize survival did not actually live longer. This raises questions about the efficacy of aggressive systemic therapy in the oldest-old with multiple GA impairments. If the survival benefit of aggressive treatment is marginal or non-existent in this demographic, the argument for prioritizing QoL becomes even more clinically and ethically compelling.
Conclusion
The secondary analysis of the GAP70+ trial serves as a critical call to action for the oncology community. While geriatric assessments have improved our ability to identify frailty, they must be coupled with robust shared decision-making (SDM) processes that actually alter the therapeutic course based on patient values. Currently, a patient’s preference for quality of life appears to have little impact on the ‘machinery’ of cancer treatment and its subsequent outcomes.
Future research must focus on developing ‘preference-concordant’ treatment algorithms. We need clinical trials that specifically test whether de-escalated therapy in QoL-prioritizing patients can maintain survival while significantly reducing the burden of treatment. For clinicians, the takeaway is clear: simply asking about a patient’s preference is the first step; the harder, more necessary step is ensuring that the answer significantly reshapes the clinical strategy.
References
- Richardson DR, Wang Y, Flannery M, et al. Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial. JAMA Oncol. 2026; PMID: 41784985.
- Mohile SG, Mohamed MR, Xu H, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398(10314):1894-1904. PMID: 34741815.
- Loh KP, Mohile SG, Lund JL, et al. Beliefs about chemotherapy and treatment adherence in older adults with cancer. J Am Geriatr Soc. 2019;67(11):2343-2349. PMID: 31334567.